To study the safety of YCT-529 in humans, we conducted a Phase 1a clinical trial where 16 healthy men received either placebo or escalating single doses of YCT-529 to assess its safety and tolerability. YCT-529 was well tolerated, and no adverse effects were noted. The positive results from this first clinical trial laid the groundwork for a second trial, where men receive YCT-529 for 28 days and 90 days, to study safety and changes in sperm parameters.

[–] xodoh74984@lemmy.world 15 points 4 days ago

It looks like the hormonal NES/T male contraceptive gel passed safety a while back and started phase 2 trials in 2018. It's already gearing up for phase 3 trials with investors ready to fund this final phase:
https://www.einpresswire.com/article/835140008/contraline-exercises-license-option-for-nes-t-the-first-male-contraceptive-to-reach-late-stage-development

But a hormone-free option is more appealing. I hope YCT-529 makes it to the finish line.